Skip to main
ORGO
ORGO logo

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc. is positioned for growth with its expansive product portfolio in regenerative medicine, addressing both advanced wound care and surgical applications. The company operates in an underpenetrated market, presenting significant opportunities for further expansion and additional total addressable market (TAM) beyond current offerings. Expectations for normalized operating dynamics in the second half of FY25 suggest a positive trajectory for financial performance as plans materialize, reinforcing a favorable outlook for the company's future growth.

Bears say

The financial outlook for Organogenesis Holdings Inc. appears negative due to several key factors, including anticipated lower growth for the PuraPly product line and challenges related to Medicare Part B pricing on amniotic products. The company is also facing heightened competition, with competitors potentially able to navigate regulatory hurdles more efficiently, which could hinder Organogenesis's market share gains. Additionally, the substantial investment of approximately $30 million in the ReNu program, coupled with delays in obtaining regulatory clearance, further adds to the negative sentiment surrounding the company's financial stability and future revenue expectations.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Nov 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.